雅本化学股份有限公司投资者关系活动记录表 证券代码：300261 证券简称：雅本化学 编号：20250613 | 投资者关系活动 | ☑特定对象调研 □分析师会议 | | | --- | --- | --- | | 类别 | □媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他（请文字说明其他活动内容） | | | 参与单位名称及 | 国联民生证券 赵嘉卉、吴君怡 | | | 人员姓名 | 华安证券 刘天其 | | | | 班培琪 建信保险资管 | | | 时间 | 2025 年 6 月 日 (周五) 下午 14:00~15:00 | 13 | | 地点 | 公司会议室 | | | 上市公司接待人 | 王一川 董秘、副总经理 | | | 员姓名 | 证券事务代表 朱佩芳 | | | 投资者关系 | 1、请介绍一下公司氯虫苯甲酰胺中间体业务及销售情况？ | | | | 子公司南通雅本化学有限公司具备 吨/年的氯虫苯甲酰 2000 | | | | 胺中间体 K 酸的产能，采用 CDMO 业务模式，可根据客户订单 | | | | 需求提供定制化生产及 ...

Core Viewpoint - The stock price of Lianhua Technology (002250.SZ) has surged significantly due to a supply-demand shock in the chlorantraniliprole market following an explosion at Youdao Chemical, which has led to a price increase in related products [1][2][4]. Group 1: Stock Performance - Lianhua Technology's stock has recorded a remarkable increase, with a rise of 5.11% on June 10, and a cumulative increase of 126% over the last 10 trading days, marked by "10 days 6 boards" [1][4]. - The stock began its upward trend on May 27, coinciding with the explosion at Youdao Chemical, which caused a significant supply reduction in chlorantraniliprole intermediates [3][4]. Group 2: Industry Impact - The explosion at Youdao Chemical, which has a production capacity of 11,000 tons for chlorantraniliprole, has led to a sharp decrease in the supply of intermediates, driving up prices for K acid and K amine, which are crucial for the production of chlorantraniliprole [3][4]. - Lianhua Technology operates under a CDMO model, providing high-end intermediates for chlorantraniliprole, and is positioned to potentially become a sole supplier of K amine in the short term, gaining market pricing power [4][5]. Group 3: Financial Performance - In Q1, Lianhua Technology reported a 3.02% increase in revenue, while net profit surged over 17 times year-on-year, reaching approximately 49.72 million yuan, and the non-recurring net profit increased by over 3 times [1][7]. - For 2024, despite an expected 11.88% decline in revenue to 5.677 billion yuan, the company anticipates a 122.17% increase in net profit to 241 million yuan, recovering from a loss of 465 million yuan in 2023 [6][7]. - The company's revenue from pesticide intermediates and pharmaceutical intermediates for 2024 is projected to be 3.59 billion yuan and 1.285 billion yuan, respectively, accounting for 63.25% and 22.63% of total revenue [7].